Merck has acquired 20 companies, including 10 in the last 5 years. A total of 5 acquisitions came from private equity firms. It has also divested 5 assets.
Merck’s largest acquisition to date was in 2009, when it acquired Schering-Plough for $41.1B. It’s largest disclosed sale occurred in 2009, when it sold Merial to Sanofi SA for $4.0B. Merck has acquired in 8 different US states, and 6 countries. The Company’s most targeted sectors include life science (90%) and information technology (5%).
Join Mergr and gain access to Merck’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.
2000 Galloping Hill Road,
Kenilworth,
New Jersey 07033
United States,
(908) 423-1000
www.merck.com
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The Company’s operations are comprised of four operating segments. These include Pharmaceutical, Animal Health, Consumer Care and Alliances. Merck's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products. Merck & Co., Inc. was established in 1891 and is based in Kenilworth, New Jersey.
| Year | ≤ '14 | '15 | '16 | '17 | '18 | '19 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (1.6/yr) | # | 12 | 1 | 2 | - | 2 | 3 | 20 |
| vol | $53.5B | $9.5B | $500M | $2.7B | $1.5B | $67.6B | ||
| Sell (0.6/yr) | # | 2 | 2 | - | - | 1 | - | 5 |
| vol | $4.0B | $75M | $4.1B | |||||
| 25 | ||||||||
| Financial | Deals |
|---|---|
|
Sign-up to View
|
3 |
|
Sign-up to View
|
1 |
|
Sign-up to View
|
1 |
| Legal | Deals |
|---|---|
|
Sign-up to View
|
2 |
|
Sign-up to View
|
1 |
|
Sign-up to View
|
1 |
| Buy | # | TOTAL |
|---|---|---|
| > $1B | Sign-up to View | |
| $100M to $1B | Sign-up to View | |
| < $100M | Sign-up to View | |
| TOTAL | Sign-up to View | |
| Largest |
Schering-Plough Corp. $41.1B (2009-11-03) |
|
| Sell | # | Total |
|---|---|---|
| > $1B | Sign-up to View | |
| $100M to $1B | Sign-up to View | |
| < $100M | Sign-up to View | |
| Total | Sign-up to View | |
| Largest |
Merial Ltd. $4.0B (2009-07-30) |
|
When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 388 life science companies that have made at least 1 acquisition, 17 have acquired at least 5 companies, and 2 have acquired more than 10 companies.
The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 22 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Avista Capital Partners with 6 platform acquisitions.
We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.
Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.
Try us for 1 week free today!
No obligation. Cancel anytime.
